VX-770, C

Heidi J Nick, Sarah E Christeson, Preston E Bratcher

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Special Issue "Research Advances on Cystic Fibrosis and CFTR Protein".International journal of molecular sciences · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Heidi J NickDepartment of Pediatrics, National Jewish Health, Denver, CO 80206, USA.ORCID 0000-0002-7853-6302

Sarah E ChristesonDepartment of Pediatrics, National Jewish Health, Denver, CO 80206, USA.

Preston E BratcherDepartment of Pediatrics, National Jewish Health, Denver, CO 80206, USA.ORCID 0000-0003-2240-8632

Funding

Contribution of pulmonary ionocytes and neuroendocrine cells to ion transport-mediated airway surface liquid maintenanceR01HL155325 · NHLBI · NATIONAL JEWISH HEALTH · PI BRATCHER, PRESTON E · 2021 to 2025

$2.3M

Cystic Fibrosis Foundation BRATCH21I0Department of Pediatrics at National Jewish Health Not ApplicableEaston M. Crawford Charitable Lead Unitrust Not ApplicableNHLBI NIH HHS R01 HL155325NIH HHS 1R01HL155325-04A1

6 · The paper itself

Abstract

The cystic fibrosis transmembrane conductance regulator (CFTR) is an anion channel that is dysfunctional in individuals with cystic fibrosis (CF). The permeability of CFTR can be experimentally manipulated though different mechanisms, including activation via inducing the phosphorylation of residues in the regulatory domain as well as altering the gating/open probability of the channel. Phosphorylation/activation of the channel is achieved by exposure to compounds that increase intracellular cAMP, with forskolin and IBMX commonly used for this purpose. C

Indexed as

AminophenolsCyclic AMPCystic Fibrosis Transmembrane Conductance RegulatorQuinolones1-Methyl-3-isobutylxanthineAnimalsBenzoatesCells, CulturedColforsinEpithelial CellsHumansIon Channel GatingRatsRats, Inbred F344ThiazolidinesThyroid Epithelial Cells1-Methyl-3-isobutylxanthine3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinoneAminophenolsBenzoatesCFTR protein, humanColforsinCyclic AMPCystic Fibrosis Transmembrane Conductance RegulatorivacaftorQuinolonesThiazolidinesairway ion transportCact-A1cAMPCFTRCFTR modulatorcystic fibrosisivacaftorVX-770

Identifiers

PMID39859187

DOI10.3390/ijms26020471

PMCPMC11764695

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.